Clinical Trial

Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The investigators hypothesize that the combination of eribulin and zanzalintinib will be tolerable and lead to improved progression-free survival (PFS) as compared to eribulin alone based on historical data.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2025-04-25; most recent amendment 2026-05-29.
Status change: Not Yet Recruiting → Recruiting 2025-10-22
Trial Details
NCT Number NCT06957431
Lead Sponsor Washington University School of Medicine
Collaborators: Exelixis
Conditions Advanced Leiomyosarcoma, Adipocytic Sarcoma, Advanced Liposarcoma
Enrollment 18 participants
Start Date 2025-10-22
Primary Completion 2031-05-31 (estimated)
Study Completion 2036-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-03